Granulocyte colony-stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission. The Fukouka Bone Marrow Transplant Group - PubMed (original) (raw)

Clinical Trial

. 1997 Oct;66(3):297-301.

doi: 10.1016/s0925-5710(97)00037-6.

K Akashi, S Hayashi, T Eto, Y Takamatsu, T Teshima, Y Hirota, S Taniguchi, K Nagafuji, S Mizuno, H Gondo, Y Niho

Affiliations

• PMID: 9401275
• DOI: 10.1016/s0925-5710(97)00037-6

Clinical Trial

Granulocyte colony-stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission. The Fukouka Bone Marrow Transplant Group

M Harada et al. Int J Hematol. 1997 Oct.

Abstract

We conducted a clinical trial to increase the chemosensitivity of residual leukemic cells by combining G-CSF to marrow-ablative chemotherapy, including cytosine arabinoside (Ara-C), and facilitated by autologous blood cell transplantation (ABCT) for treatment of acute myelogenous leukemia (AML) in first complete remission. A total of 16 patients were consecutively treated with granulocyte colony-stimulating factor (G-CSF)-combined high-dose chemotherapy (busulfan, etoposide and Ara-C) followed by autotransplantation of peripheral blood progenitor cells, which had been collected after the consolidation chemotherapy. At a median follow-up time of 44.5 months, the probability of 5-year event-free survival was 74.5% with only three leukemic relapses. This preliminary observation suggests the effectiveness of G-CSF-combined conditioning and ABCT as a post-remission therapy for AML.

PubMed Disclaimer

Similar articles

• Autologous peripheral blood progenitor cell transplantation mobilized with high-dose cytarabine in acute myeloid leukemia in first complete remission.
  Pavlovsky S, Fernández I, Milone G, Martinez Rolón J, Corrado C, Desmery P, Dignani C, Michelet M, Juni M. Pavlovsky S, et al. Ann Oncol. 1998 Feb;9(2):151-7. doi: 10.1023/a:1008271624978. Ann Oncol. 1998. PMID: 9553659 Clinical Trial.
• Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
  Lemoli RM, Visani G, Leopardi G, Motta MR, Rizzi S, Testoni N, Curti A, Tura S. Lemoli RM, et al. Bone Marrow Transplant. 1999 Feb;23(3):235-41. doi: 10.1038/sj.bmt.1701576. Bone Marrow Transplant. 1999. PMID: 10084254
• Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia.
  Demirer T, Buckner CD, Appelbaum FR, Petersen FB, Rowley S, Weaver CH, Lilleby K, Sanders J, Chauncey T, Storb R, et al. Demirer T, et al. Bone Marrow Transplant. 1995 Jun;15(6):915-22. Bone Marrow Transplant. 1995. PMID: 7581091
• Treatment of acute myelogenous leukaemia.
  Löwenberg B. Löwenberg B. J Intern Med Suppl. 1997;740:17-22. J Intern Med Suppl. 1997. PMID: 9350177 Review.
• The EORTC trials for acute myelogenous leukemia. EORTC Leukemia Cooperative Group. European Organisation of Research and Treatment of Cancer.
  Zittoun R. Zittoun R. Hematol Cell Ther. 1996 Jul;38(3):247-52. doi: 10.1007/s00282-996-0247-x. Hematol Cell Ther. 1996. PMID: 8974788 Review.

Cited by

• Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission.
  Miyamoto T, Nagafuji K, Fujisaki T, Uchida N, Matsue K, Henzan H, Ogawa R, Takase K, Aoki T, Hidaka M, Teshima T, Taniguchi S, Akashi K, Harada M; Japan Study Group for Cell Therapy and Transplantation (JSCT). Miyamoto T, et al. Int J Hematol. 2018 Apr;107(4):468-477. doi: 10.1007/s12185-017-2389-8. Epub 2017 Dec 14. Int J Hematol. 2018. PMID: 29243031 Clinical Trial.
• A variant form of acute promyelocytic leukemia with marked myelofibrosis.
  Fukuno K, Tsurumi H, Yoshikawa T, Yamada T, Oyama M, Moriwaki H. Fukuno K, et al. Int J Hematol. 2001 Oct;74(3):322-6. doi: 10.1007/BF02982068. Int J Hematol. 2001. PMID: 11721970
• AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation.
  Miyamoto T, Weissman IL, Akashi K. Miyamoto T, et al. Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7521-6. doi: 10.1073/pnas.97.13.7521. Proc Natl Acad Sci U S A. 2000. PMID: 10861016 Free PMC article.
• Advances in therapies for acute promyelocytic leukemia.
  Kamimura T, Miyamoto T, Harada M, Akashi K. Kamimura T, et al. Cancer Sci. 2011 Nov;102(11):1929-37. doi: 10.1111/j.1349-7006.2011.02045.x. Epub 2011 Aug 24. Cancer Sci. 2011. PMID: 21790894 Free PMC article. Review.
• Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
  Sanz J, Labopin M, Pabst T, Versluis J, Van Gorkom G, Meijer E, Gedde-Dahl T, Montoro J, Arcese W, Pérez-Simón JA, Schaap N, Maertens J, Vrhovac R, Lanza F, Gorin NC, Mohty M, Ciceri F. Sanz J, et al. Bone Marrow Transplant. 2023 Nov;58(11):1197-1202. doi: 10.1038/s41409-023-02075-4. Epub 2023 Aug 8. Bone Marrow Transplant. 2023. PMID: 37553468

Publication types

MeSH terms

Substances

LinkOut - more resources

• Medical

  • MedlinePlus Health Information